X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
D | 2025-02-13 | NBIX | Cooke Julie | CHRO | S - Sale+OE | $116.78 | -1,551 | 20,190 | -7% | -$181,129 | |||||
D | 2025-02-13 | NBIX | Gorman Kevin Charles | Dir | S - Sale+OE | $116.69 | -5,844 | 524,209 | -1% | -$681,914 | |||||
2025-02-13 | NBIX | Sherwin Stephen A | Dir | S - Sale | $116.69 | -13,831 | 10,673 | -56% | -$1,613,923 | ||||||
DM | 2025-02-13 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale+OE | $116.44 | -2,218 | 35,640 | -6% | -$258,264 | |||||
D | 2025-02-13 | NBIX | Onyia Jude | Chief Scientific Officer | S - Sale+OE | $116.79 | -2,879 | 18,089 | -14% | -$336,239 | |||||
D | 2025-02-13 | NBIX | Lippoldt Darin | GC | S - Sale+OE | $116.76 | -2,184 | 43,405 | -5% | -$254,992 | |||||
D | 2025-02-13 | NBIX | Gano Kyle | CEO | S - Sale+OE | $116.85 | -2,558 | 139,907 | -2% | -$298,908 | |||||
D | 2025-02-13 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $116.71 | -1,471 | 4,730 | -24% | -$171,674 | |||||
D | 2025-02-13 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale+OE | $116.74 | -1,785 | 3,565 | -33% | -$208,387 | |||||
D | 2025-02-13 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $116.73 | -2,154 | 44,689 | -5% | -$251,428 | |||||
D | 2025-02-13 | NBIX | Abernethy Matt | CFO | S - Sale+OE | $116.86 | -2,558 | 35,810 | -7% | -$298,923 | |||||
D | 2025-02-10 | NBIX | Cooke Julie | CHRO | S - Sale+OE | $118.28 | -700 | 18,831 | -4% | -$82,793 | |||||
D | 2025-02-10 | NBIX | Gorman Kevin Charles | Dir | S - Sale+OE | $118.37 | -2,274 | 519,074 | 0% | -$269,167 | |||||
D | 2025-02-10 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale+OE | $118.22 | -980 | 33,253 | -3% | -$115,853 | |||||
D | 2025-02-10 | NBIX | Lippoldt Darin | GC | S - Sale+OE | $118.25 | -911 | 41,679 | -2% | -$107,727 | |||||
D | 2025-02-10 | NBIX | Gano Kyle | CEO | S - Sale+OE | $118.39 | -980 | 137,658 | -1% | -$116,020 | |||||
D | 2025-02-10 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale+OE | $118.31 | -700 | 1,998 | -26% | -$82,820 | |||||
D | 2025-02-10 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $118.31 | -980 | 42,799 | -2% | -$115,940 | |||||
D | 2025-02-10 | NBIX | Abernethy Matt | CFO | S - Sale+OE | $118.27 | -980 | 33,561 | -3% | -$115,909 | |||||
D | 2025-01-31 | NBIX | Cooke Julie | CHRO | S - Sale+OE | $152.89 | -1,740 | 18,202 | -9% | -$266,025 | |||||
D | 2025-01-31 | NBIX | Gorman Kevin Charles | Dir | S - Sale+OE | $152.93 | -2,707 | 517,030 | -1% | -$413,967 | |||||
D | 2025-01-31 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale+OE | $152.81 | -1,457 | 32,373 | -4% | -$222,636 | |||||
D | 2025-01-31 | NBIX | Onyia Jude | Chief Scientific Officer | S - Sale+OE | $152.97 | -126 | 15,561 | -1% | -$19,274 | |||||
D | 2025-01-31 | NBIX | Lippoldt Darin | GC | S - Sale+OE | $152.91 | -1,250 | 40,863 | -3% | -$191,133 | |||||
D | 2025-01-31 | NBIX | Gano Kyle | CEO | S - Sale+OE | $152.87 | -1,541 | 136,778 | -1% | -$235,577 | |||||
DM | 2025-01-31 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $150.81 | -1,045 | 3,442 | -23% | -$157,594 | |||||
D | 2025-01-31 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale+OE | $152.94 | -1,104 | 1,369 | -45% | -$168,849 | |||||
D | 2025-01-31 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $152.94 | -1,207 | 41,919 | -3% | -$184,599 | |||||
D | 2025-01-31 | NBIX | Abernethy Matt | CFO | S - Sale+OE | $152.87 | -1,283 | 32,681 | -4% | -$196,136 | |||||
D | 2025-01-27 | NBIX | Gorman Kevin Charles | Dir | S - Sale+OE | $149.46 | -146,105 | 514,596 | -22% | -$21,836,503 | |||||
D | 2025-01-15 | NBIX | Gano Kyle | CEO | S - Sale+OE | $141.50 | -65,000 | 135,392 | -32% | -$9,197,550 | |||||
D | 2024-12-31 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $138.10 | -272 | 2,507 | -10% | -$37,563 | |||||
D | 2024-12-17 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $135.00 | -1,091 | 2,507 | -30% | -$147,285 | |||||
D | 2024-11-29 | NBIX | Onyia Jude | Chief Scientific Officer | S - Sale+OE | $126.29 | -2,331 | 15,449 | -13% | -$294,373 | |||||
2024-09-13 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $121.88 | -3,461 | 1,672 | -67% | -$421,828 | ||||||
2024-08-15 | NBIX | Rastetter William H | Dir | S - Sale | $146.69 | -14,250 | 37,491 | -28% | -$2,090,333 | ||||||
D | 2024-08-13 | NBIX | Lyons Gary A | Dir | S - Sale+OE | $150.43 | -11,570 | 119,047 | -9% | -$1,740,450 | |||||
D | 2024-08-13 | NBIX | Abernethy Matt | CFO | S - Sale+OE | $150.38 | -14,100 | 31,528 | -31% | -$2,120,347 | |||||
D | 2024-08-13 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $150.10 | -7,143 | 2,507 | -74% | -$1,072,180 | |||||
D | 2024-08-06 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $147.70 | -273 | 6,607 | -4% | -$40,322 | |||||
D | 2024-08-01 | NBIX | Cooke Julie | CHRO | S - Sale+OE | $153.26 | -12,632 | 18,202 | -41% | -$1,936,017 | |||||
D | 2024-08-01 | NBIX | Lippoldt Darin | GC | S - Sale+OE | $154.01 | -2,996 | 39,740 | -7% | -$461,423 | |||||
D | 2024-07-16 | NBIX | Cooke Julie | CHRO | S - Sale+OE | $150.04 | -900 | 18,202 | -5% | -$135,036 | |||||
D | 2024-07-16 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $150.03 | -2,857 | 6,607 | -30% | -$428,627 | |||||
D | 2024-07-16 | NBIX | Lyons Gary A | Dir | S - Sale+OE | $150.03 | -930 | 119,047 | -1% | -$139,530 | |||||
D | 2024-07-16 | NBIX | Abernethy Matt | CFO | S - Sale+OE | $150.04 | -900 | 31,528 | -3% | -$135,037 | |||||
D | 2024-07-16 | NBIX | Lippoldt Darin | GC | S - Sale+OE | $150.00 | -7,004 | 39,740 | -15% | -$1,050,590 | |||||
D | 2024-07-01 | NBIX | Cooke Julie | CHRO | S - Sale+OE | $140.19 | -10,000 | 18,202 | -35% | -$1,401,864 | |||||
D | 2024-07-01 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $138.11 | -272 | 7,507 | -3% | -$37,566 | |||||
D | 2024-05-31 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $136.55 | -273 | 7,507 | -4% | -$37,278 | |||||
D | 2024-05-29 | NBIX | Sherwin Stephen A | Dir | S - Sale+OE | $133.46 | -40,000 | 26,504 | -60% | -$5,338,565 | |||||
D | 2024-05-17 | NBIX | Sharp Shalini | Dir | S - Sale+OE | $141.90 | -1,106 | 994 | -53% | -$156,943 | |||||
D | 2024-05-17 | NBIX | Pops Richard F | Dir | S - Sale+OE | $141.84 | -2,100 | 31,611 | -6% | -$297,860 | |||||
D | 2024-05-17 | NBIX | Norwalk Leslie V | Dir | S - Sale+OE | $141.82 | -1,106 | 994 | -53% | -$156,850 | |||||
D | 2024-05-14 | NBIX | Lyons Gary A | Dir | S - Sale+OE | $135.63 | -12,500 | 116,947 | -10% | -$1,695,370 | |||||
DM | 2024-05-14 | NBIX | Abernethy Matt | CFO | S - Sale+OE | $137.95 | -30,000 | 31,528 | -49% | -$4,138,436 | |||||
D | 2024-05-06 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $140.55 | -273 | 7,507 | -4% | -$38,370 | |||||
D | 2024-04-15 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $133.37 | -19,818 | 40,778 | -33% | -$2,643,020 | |||||
D | 2024-04-01 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $137.30 | -272 | 7,507 | -3% | -$37,346 | |||||
D | 2024-03-21 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $145.06 | -5,000 | 7,507 | -40% | -$725,320 | |||||
D | 2024-03-14 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $139.38 | -75,000 | 40,778 | -65% | -$10,453,418 | |||||
D | 2024-03-14 | NBIX | Morrow George J | Dir | S - Sale+OE | $139.42 | -40,000 | 0 | -100% | -$5,576,710 | |||||
D | 2024-03-13 | NBIX | Pops Richard F | Dir | S - Sale+OE | $140.33 | -23,200 | 29,512 | -44% | -$3,255,621 | |||||
D | 2024-03-13 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $140.14 | -3,000 | 7,507 | -29% | -$420,419 | |||||
DM | 2024-03-08 | NBIX | Pops Richard F | Dir | S - Sale+OE | $140.04 | -1,800 | 29,512 | -6% | -$252,078 | |||||
DM | 2024-03-08 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $140.03 | -2,000 | 7,507 | -21% | -$280,053 | |||||
DM | 2024-02-28 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $135.34 | -6,817 | 7,507 | -48% | -$922,632 | |||||
D | 2024-02-28 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $134.69 | -75,000 | 40,616 | -65% | -$10,101,608 | |||||
D | 2024-02-27 | NBIX | Norwalk Leslie V | Dir | S - Sale+OE | $135.67 | -8,000 | 0 | -100% | -$1,085,388 | |||||
D | 2024-02-20 | NBIX | Pops Richard F | Dir | S - Sale+OE | $132.47 | -15,000 | 29,512 | -34% | -$1,987,047 | |||||
D | 2024-02-13 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale+OE | $132.96 | -1,114 | 23,716 | -4% | -$148,122 | |||||
D | 2024-02-13 | NBIX | Onyia Jude | Chief Scientific Officer | S - Sale+OE | $132.94 | -1,432 | 13,128 | -10% | -$190,371 | |||||
D | 2024-02-13 | NBIX | Lippoldt Darin | GC | S - Sale+OE | $133.00 | -1,098 | 39,740 | -3% | -$146,028 | |||||
D | 2024-02-13 | NBIX | Gorman Kevin Charles | CEO | S - Sale+OE | $133.02 | -2,832 | 514,596 | -1% | -$376,700 | |||||
D | 2024-02-13 | NBIX | Gano Kyle | Chief Business Development Off | S - Sale+OE | $132.90 | -1,352 | 135,166 | -1% | -$179,674 | |||||
D | 2024-02-13 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $133.04 | -716 | 7,507 | -9% | -$95,253 | |||||
D | 2024-02-13 | NBIX | Cooke Julie | CHRO | S - Sale+OE | $133.04 | -796 | 17,976 | -4% | -$105,902 | |||||
D | 2024-02-13 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale+OE | $133.07 | -1,811 | 4,895 | -27% | -$240,996 | |||||
D | 2024-02-13 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $133.02 | -1,098 | 40,616 | -3% | -$146,050 | |||||
D | 2024-02-13 | NBIX | Abernethy Matt | CFO | S - Sale+OE | $132.85 | -1,352 | 31,528 | -4% | -$179,612 | |||||
M | 2024-02-06 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $137.09 | -1,784 | 4,895 | -27% | -$244,564 | |||||
M | 2024-02-06 | NBIX | Cooke Julie | CHRO | S - Sale | $138.61 | -2,544 | 17,263 | -13% | -$352,612 | |||||
M | 2024-02-06 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale | $138.49 | -2,101 | 22,717 | -8% | -$290,968 | |||||
M | 2024-02-06 | NBIX | Lippoldt Darin | GC | S - Sale | $138.47 | -1,952 | 38,755 | -5% | -$270,284 | |||||
M | 2024-02-06 | NBIX | Gorman Kevin Charles | CEO | S - Sale | $138.74 | -5,314 | 506,962 | -1% | -$737,271 | |||||
M | 2024-02-06 | NBIX | Gano Kyle | Chief Business Development Off | S - Sale | $139.16 | -2,580 | 133,952 | -2% | -$359,041 | |||||
M | 2024-02-06 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale | $138.68 | -2,260 | 39,631 | -5% | -$313,419 | |||||
M | 2024-02-06 | NBIX | Abernethy Matt | CFO | S - Sale | $138.73 | -2,260 | 30,314 | -7% | -$313,530 | |||||
2024-01-31 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale | $140.79 | -1,457 | 20,832 | -7% | -$205,132 | ||||||
2024-01-31 | NBIX | Onyia Jude | Chief Scientific Officer | S - Sale | $141.94 | -126 | 11,843 | -1% | -$17,884 | ||||||
2024-01-31 | NBIX | Lippoldt Darin | GC | S - Sale | $140.65 | -1,250 | 37,005 | -3% | -$175,810 | ||||||
2024-01-31 | NBIX | Gorman Kevin Charles | CEO | S - Sale | $140.69 | -2,707 | 502,188 | -1% | -$380,845 | ||||||
2024-01-31 | NBIX | Gano Kyle | Chief Business Development Off | S - Sale | $140.70 | -1,541 | 131,635 | -1% | -$216,813 | ||||||
M | 2024-01-31 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale | $140.65 | -1,045 | 6,865 | -13% | -$146,975 | |||||
2024-01-31 | NBIX | Cooke Julie | CHRO | S - Sale | $141.29 | -1,740 | 17,263 | -9% | -$245,842 | ||||||
2024-01-31 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $140.80 | -2,096 | 4,894 | -30% | -$295,115 | ||||||
2024-01-31 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale | $140.78 | -1,207 | 37,601 | -3% | -$169,927 | ||||||
2024-01-31 | NBIX | Abernethy Matt | CFO | S - Sale | $140.72 | -1,283 | 28,284 | -4% | -$180,539 | ||||||
D | 2024-01-22 | NBIX | Lippoldt Darin | GC | S - Sale+OE | $139.86 | -10,000 | 35,882 | -22% | -$1,398,553 | |||||
DM | 2024-01-08 | NBIX | Gorman Kevin Charles | CEO | S - Sale+OE | $133.02 | -167,858 | 499,754 | -25% | -$22,328,417 |
A | Amended filing |
D | Derivative transaction in filing (usually option exercise) |
E | Error detected in filing |
M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
S - Sale | Sale of securities on an exchange or to another person |
S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
P - Purchase | Purchase of securities on an exchange or from another person |